azithromycin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, produced by Streptomyces strains 276 83905-01-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • CP-62993
  • CP 62993
  • azithromycin
  • arzomicin
  • aziromycin
  • Azithromycin A
  • azithromycin monohydrate
  • azithromycin anhydrous
  • azithromycin dihydrate
  • azithromycin hydrate
A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis. Some evidence of in vitro activity against SARS-CoV-2 in infected Vero E6 and Caco-2 cells has been reported but clinical importance it is unclear. Only limited information available regarding the frequency and microbiology of bacterial pulmonary coinfections or superinfections in pacients with COVID-19.
  • Molecular weight: 749.00
  • Formula: C38H72N2O12
  • CLOGP: 2.64
  • LIPINSKI: 2
  • HAC: 14
  • HDO: 5
  • TPSA: 180.08
  • ALOGS: -3.16
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O
0.50 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 39 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 6 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 44.50 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 34 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 33 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.88 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 69 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 1, 1991 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 1559.17 9.50 1916 71831 241909 46370406
Infective pulmonary exacerbation of cystic fibrosis 618.04 9.50 314 73433 10493 46601822
Abortion incomplete 537.05 9.50 200 73547 3064 46609251
Cystic fibrosis 233.91 9.50 115 73632 3573 46608742
Abortion spontaneous 217.86 9.50 305 73442 43341 46568974
Completed suicide 183.36 9.50 12 73735 145908 46466407
Off label use 182.16 9.50 1122 72625 378719 46233596
Cholecystitis chronic 158.49 9.50 132 73615 10367 46601948
Haemorrhage 155.76 9.50 297 73450 54572 46557743
Injury 150.02 9.50 258 73489 43769 46568546
Rheumatoid arthritis 140.06 9.50 105 73642 240110 46372205
Product packaging quantity issue 131.28 9.50 54 73693 1090 46611225
Electrocardiogram QT prolonged 121.95 9.50 258 73489 51067 46561248
COVID-19 106.63 9.50 139 73608 18436 46593879
Emotional distress 105.97 9.50 181 73566 30526 46581789
Bronchiectasis 102.58 9.50 98 73649 9218 46603097
Asthma 99.87 9.50 345 73402 91197 46521118
Cough 95.80 9.50 657 73090 229592 46382723
Contraindicated product administered 88.53 9.50 11 73736 79936 46532379
No adverse event 88.26 9.50 178 73569 34053 46578262
Joint swelling 86.37 9.50 81 73666 165992 46446323
Pneumonia 85.55 9.50 939 72808 375381 46236934
Product use in unapproved indication 79.85 9.50 318 73429 89955 46522360
Exposure during pregnancy 79.31 9.50 360 73387 107852 46504463
Wheezing 76.37 9.50 221 73526 53165 46559150
Pulmonary function test decreased 72.59 9.50 55 73692 3765 46608550
Biliary dyskinesia 71.31 9.50 48 73699 2725 46609590
Anosmia 71.03 9.50 55 73692 3889 46608426
Pulmonary embolism 69.94 9.50 348 73399 108237 46504078
Arthralgia 69.52 9.50 318 73429 364285 46248030
Mycobacterium avium complex infection 68.49 9.50 46 73701 2602 46609713
Bronchitis 65.69 9.50 336 73411 105643 46506672
Intentional overdose 64.89 9.50 12 73735 64932 46547383
Sinusitis 64.14 9.50 387 73360 129381 46482934
Infusion related reaction 63.18 9.50 41 73706 101167 46511148
Death 62.56 9.50 295 73452 335253 46277062
Long QT syndrome 62.22 9.50 46 73701 3034 46609281
Toxicity to various agents 62.06 9.50 153 73594 211613 46400702
Fall 60.95 9.50 290 73457 328807 46283508
Productive cough 59.56 9.50 196 73551 50519 46561796
Haemoptysis 58.00 9.50 128 73619 26061 46586254
Maternal exposure during pregnancy 57.98 9.50 317 73430 102232 46510083
Synovitis 55.50 9.50 14 73733 61061 46551254
Therapeutic product effect decreased 54.99 9.50 31 73716 82570 46529745
Factor V inhibition 54.08 9.50 17 73730 150 46612165
Infective exacerbation of bronchiectasis 53.73 9.50 21 73726 369 46611946
Gallbladder disorder 53.71 9.50 98 73649 17400 46594915
Eosinophilic pneumonia 53.25 9.50 35 73712 1909 46610406
Upper respiratory tract infection 52.30 9.50 219 73528 63337 46548978
Sputum discoloured 51.76 9.50 81 73666 12697 46599618
Pathogen resistance 50.75 9.50 55 73692 6005 46606310
Cystic fibrosis respiratory infection suppression 50.06 9.50 21 73726 446 46611869
Cholelithiasis 48.60 9.50 153 73594 38528 46573787
Rhinitis allergic 48.16 9.50 57 73690 6851 46605464
Product quality issue 45.70 9.50 142 73605 35506 46576809
Chronic kidney disease 45.37 9.50 155 73592 40716 46571599
Drug abuse 44.86 9.50 22 73725 63386 46548929
Deafness 43.14 9.50 85 73662 15983 46596332
Pregnancy 40.41 9.50 114 73633 27023 46585292
Hand deformity 40.18 9.50 4 73743 34570 46577745
Systemic lupus erythematosus 39.86 9.50 27 73720 65153 46547162
Asthma-chronic obstructive pulmonary disease overlap syndrome 39.45 9.50 18 73729 471 46611844
Product dose omission issue 38.81 9.50 422 73325 168098 46444217
Drug-induced liver injury 38.19 9.50 107 73640 25261 46587054
Respiratory failure 37.81 9.50 268 73479 94548 46517767
Malignant neoplasm progression 36.97 9.50 29 73718 64897 46547418
Drug interaction 36.44 9.50 485 73262 202609 46409706
Nasal polyps 35.89 9.50 29 73718 2181 46610134
Forced expiratory volume decreased 35.39 9.50 42 73705 5062 46607253
Sputum increased 34.96 9.50 26 73721 1730 46610585
Torsade de pointes 34.71 9.50 66 73681 12088 46600227
Dysbiosis 34.66 9.50 17 73730 525 46611790
Arthropathy 34.63 9.50 50 73697 84650 46527665
Somnolence 34.42 9.50 129 73618 156392 46455923
Alopecia 34.34 9.50 136 73611 162278 46450037
Hypoxia 33.95 9.50 167 73580 51671 46560644
Myasthenia gravis crisis 33.92 9.50 15 73732 364 46611951
Auscultation 32.71 9.50 6 73741 0 46612315
Treatment failure 32.42 9.50 61 73686 93026 46519289
Suicide attempt 32.07 9.50 24 73723 55012 46557303
Pseudomonas infection 31.67 9.50 56 73691 9702 46602613
Tinnitus 31.63 9.50 106 73641 27567 46584748
Drug ineffective 31.59 9.50 823 72924 677015 45935300
Drug reaction with eosinophilia and systemic symptoms 31.00 9.50 110 73637 29438 46582877
Cystic fibrosis pancreatic 30.96 9.50 9 73738 59 46612256
Wound 30.04 9.50 15 73732 42787 46569528
Urticaria 29.84 9.50 301 73446 117591 46494724
Mobility decreased 29.80 9.50 31 73716 60563 46551752
Fatigue 29.69 9.50 734 73013 607963 46004352
Overdose 29.58 9.50 74 73673 101905 46510410
Chronic obstructive pulmonary disease 29.15 9.50 173 73574 57460 46554855
Total lung capacity increased 28.97 9.50 17 73730 757 46611558
Cystic fibrosis lung 28.69 9.50 10 73737 125 46612190
Deep vein thrombosis 28.11 9.50 219 73528 79554 46532761
Ventricular fibrillation 27.52 9.50 58 73689 11438 46600877
Mechanical urticaria 27.39 9.50 13 73734 373 46611942
Lip oedema 27.24 9.50 30 73717 3334 46608981
Congenital absence of cranial vault 26.94 9.50 7 73740 28 46612287
Gallbladder injury 26.59 9.50 20 73727 1354 46610961
Injection site pain 26.46 9.50 84 73663 107068 46505247
Middle lobe syndrome 26.37 9.50 7 73740 31 46612284
COVID-19 pneumonia 26.17 9.50 29 73718 3246 46609069
Hyponatraemia 26.04 9.50 78 73669 101254 46511061
Obstructive airways disorder 25.77 9.50 62 73685 13350 46598965
Device expulsion 25.63 9.50 6 73741 27536 46584779
Mycobacterial infection 25.62 9.50 21 73726 1612 46610703
Stevens-Johnson syndrome 25.54 9.50 88 73659 23209 46589106
Ageusia 25.31 9.50 56 73691 11416 46600899
Pelvic inflammatory disease 25.25 9.50 21 73726 1645 46610670
Dyspnoea 25.22 9.50 1024 72723 514524 46097791
Gastroenteritis staphylococcal 24.38 9.50 8 73739 82 46612233
Obliterative bronchiolitis 24.09 9.50 21 73726 1754 46610561
Distal intestinal obstruction syndrome 24.05 9.50 12 73735 385 46611930
Ototoxicity 23.95 9.50 17 73730 1052 46611263
Respiratory tract infection 23.65 9.50 102 73645 29870 46582445
Delusional disorder, persecutory type 23.46 9.50 9 73738 150 46612165
Anhedonia 23.43 9.50 51 73696 10284 46602031
Factor V deficiency 23.40 9.50 8 73739 94 46612221
Peripheral swelling 23.32 9.50 150 73597 157921 46454394
Coma 23.30 9.50 35 73712 58314 46554001
Injection site erythema 23.18 9.50 52 73695 74375 46537940
Alveolitis 23.16 9.50 24 73723 2489 46609826
Premature delivery 23.02 9.50 82 73665 21987 46590328
Endometritis 22.93 9.50 16 73731 963 46611352
Bronchial wall thickening 22.85 9.50 15 73732 816 46611499
Hypotension 22.83 9.50 246 73501 232343 46379972
Epidermolysis 22.52 9.50 10 73737 245 46612070
Drug intolerance 22.49 9.50 138 73609 146911 46465404
Rales 22.37 9.50 48 73699 9583 46602732
Anxiety 22.10 9.50 407 73340 181550 46430765
Rheumatoid factor 21.86 9.50 7 73740 66 46612249
Granulomatosis with polyangiitis 21.84 9.50 20 73727 1782 46610533
Abdominal pain 21.82 9.50 496 73251 229535 46382780
Gastrointestinal haemorrhage 21.77 9.50 57 73690 77316 46534999
Hospitalisation 21.77 9.50 173 73574 63212 46549103
Stenotrophomonas infection 21.65 9.50 19 73728 1601 46610714
Lung transplant rejection 21.44 9.50 14 73733 755 46611560
Febrile neutropenia 21.44 9.50 77 73670 94550 46517765
Gallbladder cholesterolosis 21.24 9.50 14 73733 767 46611548
Neutropenia 21.07 9.50 136 73611 143068 46469247
Urinary tract infection 20.80 9.50 235 73512 220031 46392284
Glossodynia 20.39 9.50 24 73723 44349 46567966
Platelet count decreased 20.34 9.50 85 73662 99939 46512376
Amniotic cavity infection 20.29 9.50 16 73731 1162 46611153
Pulmonary infarction 20.23 9.50 23 73724 2648 46609667
Uterine perforation 20.18 9.50 39 73708 7228 46605087
Injection site bruising 20.18 9.50 16 73731 35620 46576695
Chest discomfort 19.81 9.50 224 73523 90045 46522270
Bronchopulmonary aspergillosis allergic 19.39 9.50 13 73734 733 46611582
Breath sounds abnormal 19.38 9.50 40 73707 7775 46604540
Hepatic enzyme increased 18.89 9.50 66 73681 81721 46530594
Musculoskeletal stiffness 18.87 9.50 85 73662 97908 46514407
Acute generalised exanthematous pustulosis 18.64 9.50 44 73703 9361 46602954
Immunodeficiency common variable 18.51 9.50 7 73740 112 46612203
Breast cancer 18.47 9.50 27 73720 45491 46566824
Hypokalaemia 17.78 9.50 75 73672 87949 46524366
Respiratory tract congestion 17.44 9.50 52 73695 12712 46599603
Mucocutaneous candidiasis 17.43 9.50 4 73743 8 46612307
Neutrophil count decreased 17.39 9.50 26 73721 43400 46568915
Agranulocytosis 17.12 9.50 75 73672 22110 46590205
Knee arthroplasty 17.05 9.50 8 73739 23657 46588658
Pancreatic failure 17.02 9.50 11 73736 583 46611732
Diabetic ketoacidosis 16.88 9.50 4 73743 18206 46594109
Total lung capacity decreased 16.85 9.50 14 73733 1095 46611220
Biliary colic 16.78 9.50 24 73723 3474 46608841
Oropharyngeal pain 16.70 9.50 185 73562 73983 46538332
Bronchial secretion retention 16.65 9.50 13 73734 930 46611385
Actinic keratosis 16.48 9.50 19 73728 2220 46610095
Eosinophilia 16.41 9.50 67 73680 19150 46593165
Portal hypertensive enteropathy 16.36 9.50 3 73744 0 46612315
Staphylococcus test positive 16.33 9.50 24 73723 3560 46608755
Injection site swelling 16.29 9.50 24 73723 40303 46572012
Biopsy colon abnormal 16.23 9.50 5 73742 41 46612274
Gait disturbance 16.17 9.50 149 73598 145114 46467201
Neisseria infection 15.92 9.50 5 73742 44 46612271
Cystic fibrosis related diabetes 15.92 9.50 5 73742 44 46612271
Kounis syndrome 15.87 9.50 14 73733 1188 46611127
Pyrexia 15.68 9.50 687 73060 348115 46264200
Blood pressure fluctuation 15.63 9.50 15 73732 30433 46581882
Drug ineffective for unapproved indication 15.45 9.50 59 73688 16354 46595961
Hypoxic-ischaemic encephalopathy 15.37 9.50 25 73722 4048 46608267
Sputum retention 15.05 9.50 9 73738 415 46611900
Neural tube defect 15.00 9.50 7 73740 193 46612122
Mycoplasma infection 14.96 9.50 9 73738 420 46611895
Forced vital capacity decreased 14.94 9.50 12 73735 895 46611420
Ear discomfort 14.91 9.50 33 73714 6728 46605587
Pharyngeal enanthema 14.84 9.50 5 73742 56 46612259
Anaesthesia 14.84 9.50 5 73742 56 46612259
Respiration abnormal 14.74 9.50 26 73721 4495 46607820
Drug effective for unapproved indication 14.70 9.50 15 73732 1527 46610788
Peak expiratory flow rate abnormal 14.64 9.50 6 73741 120 46612195
Crystal arthropathy 14.61 9.50 7 73740 205 46612110
Palmar-plantar erythrodysaesthesia syndrome 14.60 9.50 7 73740 20444 46591871
Disease risk factor 14.53 9.50 5 73742 60 46612255
Hepatocellular injury 14.53 9.50 88 73659 29434 46582881
Anal inflammation 14.37 9.50 6 73741 126 46612189
Chlamydial infection 14.35 9.50 8 73739 323 46611992
Pain in extremity 14.20 9.50 306 73441 258374 46353941
Increased bronchial secretion 14.13 9.50 15 73732 1599 46610716
C-reactive protein abnormal 14.12 9.50 8 73739 21262 46591053
Monoclonal gammopathy 14.11 9.50 10 73737 617 46611698
Pneumothorax 14.11 9.50 53 73694 14576 46597739
Hemianopia heteronymous 14.10 9.50 5 73742 66 46612249
Lung opacity 14.08 9.50 13 73734 1171 46611144
Myasthenia gravis 14.08 9.50 22 73725 3444 46608871
Pneumonia pseudomonal 14.06 9.50 17 73730 2089 46610226
Rash 14.05 9.50 693 73054 355819 46256496
Sinus congestion 13.92 9.50 49 73698 13060 46599255
Swelling 13.73 9.50 128 73619 124383 46487932
Bronchomalacia 13.71 9.50 6 73741 142 46612173
Ventricular tachycardia 13.58 9.50 58 73689 16909 46595406
Injection site haemorrhage 13.45 9.50 8 73739 20701 46591614
Osteonecrosis of jaw 13.38 9.50 21 73726 34381 46577934
Oral candidiasis 13.32 9.50 59 73688 17473 46594842
Hypertension 13.32 9.50 224 73523 196132 46416183
Disease progression 13.27 9.50 87 73660 91213 46521102
Humidity intolerance 13.24 9.50 8 73739 376 46611939
COVID-19 treatment 13.22 9.50 6 73741 155 46612160
Mucosal inflammation 13.16 9.50 26 73721 38950 46573365
Meningism 13.13 9.50 8 73739 382 46611933
Kawasaki's disease 13.07 9.50 3 73744 6 46612309
Interleukin level increased 12.99 9.50 7 73740 264 46612051
Rebound acid hypersecretion 12.99 9.50 7 73740 264 46612051
Mucosal dryness 12.93 9.50 17 73730 2273 46610042
Mixed liver injury 12.83 9.50 20 73727 3123 46609192
Orthostatic hypotension 12.83 9.50 12 73735 24646 46587669
Atypical mycobacterial infection 12.82 9.50 11 73736 899 46611416
Injection site warmth 12.81 9.50 3 73744 13769 46598546
Joint range of motion decreased 12.74 9.50 4 73743 15120 46597195
Blood count abnormal 12.72 9.50 59 73688 17819 46594496
Toxic epidermal necrolysis 12.66 9.50 69 73678 22209 46590106
Veillonella infection 12.66 9.50 4 73743 36 46612279
Eosinophil count increased 12.65 9.50 34 73713 7832 46604483
Ruptured ectopic pregnancy 12.60 9.50 8 73739 411 46611904
Altered state of consciousness 12.58 9.50 11 73736 23337 46588978
Acute respiratory failure 12.57 9.50 84 73663 29054 46583261
Acute respiratory distress syndrome 12.52 9.50 68 73679 21854 46590461
Ureteric perforation 12.47 9.50 3 73744 8 46612307
Central nervous system fungal infection 12.43 9.50 5 73742 95 46612220
Haemoglobin decreased 12.38 9.50 137 73610 128812 46483503
Lymph node abscess 12.37 9.50 4 73743 39 46612276
Dysentery 12.34 9.50 10 73737 755 46611560
Stomatococcal infection 12.34 9.50 5 73742 97 46612218
Injection site reaction 12.16 9.50 37 73710 47812 46564503
Purpura 12.15 9.50 39 73708 9919 46602396
Arthritis 12.10 9.50 72 73675 77244 46535071
Loss of consciousness 12.05 9.50 111 73636 108127 46504188
Pericarditis 12.03 9.50 12 73735 23915 46588400
Abscess bacterial 12.01 9.50 6 73741 193 46612122
Dermatosis 11.99 9.50 7 73740 309 46612006
Leukaemoid reaction 11.95 9.50 6 73741 195 46612120
Pneumomediastinum 11.87 9.50 12 73735 1209 46611106
Restrictive pulmonary disease 11.83 9.50 12 73735 1214 46611101
Dehydration 11.82 9.50 179 73568 159361 46452954
Cranial nerve paralysis 11.80 9.50 5 73742 109 46612206
Vascular parkinsonism 11.72 9.50 5 73742 111 46612204
White blood cell count decreased 11.69 9.50 117 73630 112114 46500201
Bronchopulmonary aspergillosis 11.66 9.50 32 73715 7464 46604851
Lung diffusion test decreased 11.59 9.50 9 73738 639 46611676
Product colour issue 11.55 9.50 9 73738 642 46611673
Pneumopericardium 11.55 9.50 4 73743 49 46612266
Genital ulceration 11.49 9.50 8 73739 480 46611835
BK virus infection 11.45 9.50 18 73729 2831 46609484
Tachypnoea 11.44 9.50 49 73698 14302 46598013
Low birth weight baby 11.40 9.50 26 73721 5408 46606907
Drug resistance 11.40 9.50 56 73691 17312 46595003
Psoriasis 11.37 9.50 75 73672 78529 46533786
Aphthous ulcer 11.29 9.50 37 73710 9511 46602804
Hypoacusis 11.28 9.50 64 73683 20905 46591410
Sleep disorder due to a general medical condition 11.25 9.50 20 73727 3479 46608836
Rhinorrhoea 11.24 9.50 120 73627 47545 46564770
Cholecystitis 11.23 9.50 49 73698 14417 46597898
Osteoarthritis 11.23 9.50 55 73692 61970 46550345
Therapeutic response decreased 11.23 9.50 33 73714 43112 46569203
Wrong technique in product usage process 11.21 9.50 46 73701 54376 46557939
Eye irritation 11.21 9.50 54 73693 16560 46595755
Sarcoidosis 11.18 9.50 25 73722 5134 46607181
Encephalitis protozoal 11.01 9.50 3 73744 15 46612300
Multiple allergies 11.00 9.50 31 73716 7340 46604975
Hypersensitivity pneumonitis 10.97 9.50 16 73731 2357 46609958
Brain hypoxia 10.88 9.50 8 73739 523 46611792
Immunosuppressant drug level increased 10.86 9.50 19 73728 3263 46609052
Breast cancer metastatic 10.86 9.50 4 73743 13674 46598641
Tympanic membrane hyperaemia 10.84 9.50 3 73744 16 46612299
Gallbladder hypofunction 10.83 9.50 8 73739 527 46611788
Amaurosis 10.81 9.50 8 73739 528 46611787
Catarrh 10.81 9.50 7 73740 372 46611943
Adverse drug reaction 10.79 9.50 35 73712 44327 46567988
Prolonged expiration 10.76 9.50 7 73740 375 46611940
Pneumonia aspiration 10.74 9.50 21 73726 31584 46580731
Rhinovirus infection 10.70 9.50 20 73727 3616 46608699
Heart sounds 10.65 9.50 6 73741 247 46612068
Sepsis 10.63 9.50 151 73596 135863 46476452
Basal cell carcinoma 10.62 9.50 10 73737 20477 46591838
Angina bullosa haemorrhagica 10.61 9.50 5 73742 141 46612174
Immune reconstitution inflammatory syndrome associated tuberculosis 10.61 9.50 7 73740 384 46611931
Adjustment disorder 10.51 9.50 12 73735 1387 46610928
Urethral stenosis 10.44 9.50 6 73741 257 46612058
Myocardial infarction 10.43 9.50 101 73646 97427 46514888
Palmar erythema 10.37 9.50 12 73735 1408 46610907
Vulvovaginal inflammation 10.35 9.50 8 73739 564 46611751
Therapy interrupted 10.33 9.50 39 73708 10752 46601563
Cardiac failure 10.24 9.50 79 73668 79869 46532446
Seasonal allergy 10.23 9.50 45 73702 13289 46599026
HIV-associated neurocognitive disorder 10.18 9.50 5 73742 155 46612160
Hepato-lenticular degeneration 10.15 9.50 3 73744 21 46612294
Joint stiffness 10.12 9.50 17 73730 27091 46585224
HIV infection 10.10 9.50 8 73739 585 46611730
Viral infection 10.09 9.50 82 73665 30153 46582162
Lip squamous cell carcinoma 10.09 9.50 5 73742 158 46612157
Erythema multiforme 10.07 9.50 36 73711 9668 46602647
Congenital cystic lung 10.03 9.50 3 73744 22 46612293
Confusional state 10.01 9.50 185 73562 159707 46452608
Leukopenia 9.99 9.50 65 73682 68278 46544037
Deafness neurosensory 9.99 9.50 22 73725 4472 46607843
Herpes simplex viraemia 9.92 9.50 5 73742 164 46612151
Sopor 9.91 9.50 10 73737 19818 46592497
Hepatitis cholestatic 9.89 9.50 28 73719 6649 46605666
Urosepsis 9.87 9.50 6 73741 15347 46596968
Metabolic acidosis 9.85 9.50 30 73717 38750 46573565
Gastrointestinal mucosa hyperaemia 9.81 9.50 5 73742 168 46612147
Cholesterosis 9.79 9.50 7 73740 438 46611877
Vulvovaginal candidiasis 9.77 9.50 16 73731 2605 46609710
Headache 9.77 9.50 638 73109 477714 46134601
Osteonecrosis 9.75 9.50 16 73731 25728 46586587
Multiple sclerosis relapse 9.72 9.50 34 73713 42091 46570224
Epilepsy 9.71 9.50 14 73733 23724 46588591
Balamuthia infection 9.70 9.50 3 73744 25 46612290
ECG signs of myocardial ischaemia 9.67 9.50 4 73743 82 46612233
Respiratory tract inflammation 9.65 9.50 7 73740 448 46611867
Carditis 9.62 9.50 4 73743 83 46612232
Pulmonary function test abnormal 9.55 9.50 11 73736 1284 46611031
Dysarthria 9.53 9.50 29 73718 37469 46574846
Pain in jaw 9.52 9.50 30 73717 38342 46573973

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 1044.27 10.41 1685 50692 247605 29652496
Infective pulmonary exacerbation of cystic fibrosis 558.28 10.41 281 52096 8291 29891810
Electrocardiogram QT prolonged 278.25 10.41 328 52049 35507 29864594
Drug hypersensitivity 227.48 10.41 420 51957 68099 29832002
Long QT syndrome 165.20 10.41 81 52296 2252 29897849
Product use in unapproved indication 150.74 10.41 371 52006 73322 29826779
Hepatitis 126.57 10.41 175 52202 22181 29877920
COVID-19 119.78 10.41 152 52225 17726 29882375
Cystic fibrosis 115.06 10.41 63 52314 2211 29897890
Hypertransaminasaemia 109.56 10.41 74 52303 3811 29896290
Drug effective for unapproved indication 105.20 10.41 47 52330 1052 29899049
Completed suicide 102.65 10.41 24 52353 99468 29800633
Immune reconstitution inflammatory syndrome 99.78 10.41 100 52277 9001 29891100
Drug abuse 99.46 10.41 13 52364 82059 29818042
Product packaging quantity issue 90.57 10.41 37 52340 659 29899442
Vanishing bile duct syndrome 85.18 10.41 35 52342 633 29899468
Fall 80.48 10.41 121 52256 181751 29718350
Stevens-Johnson syndrome 78.50 10.41 123 52254 17433 29882668
Drug ineffective for unapproved indication 78.47 10.41 96 52281 10784 29889317
Condition aggravated 78.09 10.41 459 51918 137407 29762694
No adverse event 75.07 10.41 120 52257 17299 29882802
Cough 74.86 10.41 424 51953 125218 29774883
Pneumonia 69.57 10.41 890 51487 333416 29566685
Asthma 69.54 10.41 178 52199 35996 29864105
Pulmonary function test decreased 68.10 10.41 58 52319 4237 29895864
Mycobacterium avium complex infection 67.88 10.41 48 52329 2663 29897438
Drug interaction 66.73 10.41 585 51792 198983 29701118
Haemoptysis 66.14 10.41 159 52218 30919 29869182
Ototoxicity 63.33 10.41 36 52341 1360 29898741
Death 62.62 10.41 368 52009 356915 29543186
Toxic epidermal necrolysis 61.97 10.41 112 52265 17828 29882273
Toxicity to various agents 60.51 10.41 138 52239 177045 29723056
Productive cough 59.24 10.41 149 52228 29804 29870297
Torsade de pointes 56.04 10.41 66 52311 7124 29892977
Mycobacterium abscessus infection 55.81 10.41 25 52352 563 29899538
Solar lentigo 50.91 10.41 20 52357 320 29899781
Dysplastic naevus 49.80 10.41 20 52357 340 29899761
Malignant neoplasm progression 49.17 10.41 33 52344 72254 29827847
Alanine aminotransferase increased 49.11 10.41 258 52119 74018 29826083
Pathogen resistance 47.82 10.41 66 52311 8344 29891757
Hepatitis acute 47.08 10.41 60 52317 7023 29893078
Sputum increased 46.77 10.41 33 52344 1824 29898277
Photodermatosis 46.15 10.41 20 52357 415 29899686
COVID-19 pneumonia 42.77 10.41 46 52331 4494 29895607
Obstructive airways disorder 42.63 10.41 65 52312 8994 29891107
Bronchiectasis 42.61 10.41 49 52328 5155 29894946
Eosinophil count abnormal 40.39 10.41 16 52361 262 29899839
Forced expiratory volume decreased 39.90 10.41 38 52339 3212 29896889
Myocardial infarction 39.56 10.41 102 52275 125523 29774578
Hypertriglyceridaemia 37.96 10.41 58 52319 8040 29892061
Overdose 37.33 10.41 56 52321 84281 29815820
HIV associated nephropathy 37.30 10.41 15 52362 256 29899845
Sinusitis 36.70 10.41 135 52242 33210 29866891
Pseudomonas infection 35.63 10.41 65 52312 10417 29889684
Mycobacterium chelonae infection 34.07 10.41 18 52359 587 29899514
Wheezing 33.83 10.41 125 52252 30813 29869288
Rheumatoid arthritis 33.53 10.41 15 52362 41182 29858919
Febrile neutropenia 33.29 10.41 87 52290 106606 29793495
Somnolence 33.27 10.41 75 52302 96688 29803413
Bronchitis 33.14 10.41 146 52231 38979 29861122
Transaminases increased 32.89 10.41 103 52274 23354 29876747
Acute respiratory distress syndrome 32.85 10.41 103 52274 23369 29876732
Lung transplant rejection 32.60 10.41 19 52358 753 29899348
General physical health deterioration 32.34 10.41 80 52297 99864 29800237
Obliterative bronchiolitis 31.83 10.41 22 52355 1176 29898925
Dehydration 29.90 10.41 113 52264 123426 29776675
Intentional overdose 29.48 10.41 18 52359 41463 29858638
COVID-19 treatment 29.26 10.41 13 52364 287 29899814
Cystic fibrosis respiratory infection suppression 28.96 10.41 14 52363 377 29899724
Conjunctival hyperaemia 28.77 10.41 27 52350 2240 29897861
Product quality issue 28.72 10.41 85 52292 18689 29881412
Lung transplant 28.60 10.41 25 52352 1891 29898210
Confusional state 28.49 10.41 130 52247 134704 29765397
Lung hyperinflation 28.38 10.41 18 52359 832 29899269
Coma 28.13 10.41 18 52359 40431 29859670
Acute respiratory failure 27.89 10.41 104 52273 25746 29874355
Respiratory failure 27.53 10.41 283 52094 100359 29799742
Dizziness 27.39 10.41 214 52163 194695 29705406
Distal intestinal obstruction syndrome 26.82 10.41 13 52364 352 29899749
Liver function test increased 26.72 10.41 60 52317 11156 29888945
Jaw cyst 26.62 10.41 6 52371 9 29900092
Sputum discoloured 26.10 10.41 44 52333 6624 29893477
Scleroderma 25.40 10.41 20 52357 1307 29898794
Carbon dioxide increased 25.32 10.41 18 52359 1007 29899094
Drug resistance 25.15 10.41 85 52292 20048 29880053
Constipation 24.97 10.41 107 52270 112799 29787302
Liver injury 24.84 10.41 62 52315 12338 29887763
Lip erythema 24.65 10.41 7 52370 37 29900064
Hepatitis cholestatic 24.49 10.41 47 52330 7825 29892276
Complications of transplanted lung 24.33 10.41 10 52367 181 29899920
Total lung capacity abnormal 24.08 10.41 10 52367 186 29899915
Urethritis mycoplasmal 23.82 10.41 6 52371 18 29900083
Cystic fibrosis related diabetes 23.69 10.41 9 52368 131 29899970
Enterovirus infection 23.59 10.41 14 52363 574 29899527
Iris adhesions 23.55 10.41 10 52367 197 29899904
Aspartate aminotransferase increased 23.25 10.41 190 52187 63232 29836869
Blood immunoglobulin E increased 22.72 10.41 21 52356 1709 29898392
Rash maculovesicular 22.69 10.41 6 52371 23 29900078
Graft versus host disease in lung 22.68 10.41 13 52364 499 29899602
Viral infection 22.51 10.41 68 52309 15117 29884984
Haemolytic anaemia 22.13 10.41 52 52325 9958 29890143
Linear IgA disease 22.12 10.41 20 52357 1582 29898519
Tinnitus 21.96 10.41 70 52307 16018 29884083
Nasal mucosal disorder 21.88 10.41 8 52369 104 29899997
Decreased appetite 21.79 10.41 163 52214 149747 29750354
Gastrointestinal haemorrhage 21.72 10.41 74 52303 83372 29816729
Cytokine storm 21.09 10.41 13 52364 571 29899530
Cerebrovascular accident 21.08 10.41 75 52302 83402 29816699
Deafness 21.07 10.41 52 52325 10273 29889828
Pain 20.91 10.41 197 52180 172444 29727657
Urinary tract infection 20.79 10.41 63 52314 73596 29826505
Hepatocellular injury 20.77 10.41 94 52283 25377 29874724
Deafness neurosensory 20.38 10.41 23 52354 2370 29897731
Atypical mycobacterial lower respiratory tract infection 20.35 10.41 6 52371 37 29900064
Hospitalisation 20.33 10.41 140 52237 44179 29855922
Acoustic neuroma 20.14 10.41 8 52369 132 29899969
Tooth discolouration 20.10 10.41 10 52367 287 29899814
Pharyngeal erythema 20.06 10.41 12 52365 499 29899602
Acquired immunodeficiency syndrome 20.00 10.41 12 52365 502 29899599
Upper respiratory tract infection 19.93 10.41 98 52279 27378 29872723
Suicide attempt 19.73 10.41 21 52356 36676 29863425
Seizure 19.58 10.41 97 52280 98378 29801723
Respiratory disorder 19.39 10.41 71 52306 17423 29882678
Drug-induced liver injury 19.25 10.41 81 52296 21193 29878908
Gonorrhoea 19.21 10.41 7 52370 90 29900011
Mediastinal shift 19.17 10.41 4 52373 3 29900098
Injection site pain 19.08 10.41 15 52362 30295 29869806
Pneumothorax 19.04 10.41 67 52310 16126 29883975
Alcohol intolerance 19.03 10.41 11 52366 429 29899672
Nervous system neoplasm 19.01 10.41 8 52369 154 29899947
Clostridium difficile colitis 18.76 10.41 57 52320 12711 29887390
Breath sounds abnormal 18.57 10.41 32 52345 4903 29895198
Myasthenia gravis crisis 18.55 10.41 10 52367 340 29899761
Pneumonia legionella 18.53 10.41 18 52359 1559 29898542
Lung infiltration 18.39 10.41 56 52321 12503 29887598
Restrictive allograft syndrome 18.36 10.41 5 52372 22 29900079
Rhodococcus infection 18.16 10.41 8 52369 173 29899928
Pancreatic failure 18.07 10.41 13 52364 741 29899360
Chlamydial infection 18.03 10.41 8 52369 176 29899925
Cerebral infarction 17.97 10.41 12 52365 26361 29873740
End stage renal disease 17.96 10.41 40 52337 7395 29892706
Hypofibrinogenaemia 17.89 10.41 18 52359 1627 29898474
Forced vital capacity decreased 17.80 10.41 13 52364 759 29899342
Prostate cancer 17.58 10.41 10 52367 23947 29876154
Actinic keratosis 17.16 10.41 26 52351 3577 29896524
Oral mucosa erosion 17.12 10.41 13 52364 805 29899296
Bronchiolitis obliterans syndrome 17.08 10.41 5 52372 30 29900071
Antinuclear antibody negative 17.08 10.41 5 52372 30 29900071
Fatigue 17.02 10.41 429 51948 320244 29579857
Infective chondritis 17.02 10.41 4 52373 8 29900093
Lymph node palpable 16.94 10.41 5 52372 31 29900070
Anaemia 16.88 10.41 259 52118 207733 29692368
Hepatomegaly 16.83 10.41 47 52330 10000 29890101
Eosinophilia 16.76 10.41 80 52297 22080 29878021
Cholestasis 16.69 10.41 87 52290 24863 29875238
Rash maculo-papular 16.57 10.41 88 52289 25330 29874771
Wrong technique in product usage process 16.56 10.41 18 52359 31137 29868964
Mastocytosis 16.54 10.41 5 52372 34 29900067
Methaemoglobinaemia 16.27 10.41 21 52356 2489 29897612
Cytomegalovirus chorioretinitis 16.16 10.41 24 52353 3244 29896857
Tubulointerstitial nephritis 16.09 10.41 68 52309 17823 29882278
Senile pruritus 16.05 10.41 3 52374 0 29900101
Rash 16.01 10.41 444 51933 191445 29708656
HIV infection 15.89 10.41 17 52360 1651 29898450
Andersen-Tawil syndrome 15.88 10.41 4 52373 12 29900089
Pneumonia escherichia 15.69 10.41 9 52368 346 29899755
Palatal oedema 15.60 10.41 12 52365 758 29899343
Pseudomembranous colitis 15.55 10.41 22 52355 2846 29897255
Immunodeficiency common variable 15.53 10.41 7 52370 160 29899941
Genital ulceration 15.45 10.41 7 52370 162 29899939
Influenza 15.36 10.41 129 52248 43269 29856832
ADAMTS13 activity decreased 15.22 10.41 6 52371 97 29900004
Deafness unilateral 15.07 10.41 17 52360 1751 29898350
Hyperaemia 15.02 10.41 13 52364 970 29899131
Borderline personality disorder 15.01 10.41 9 52368 376 29899725
Red blood cell sedimentation rate decreased 14.85 10.41 5 52372 50 29900051
CD4 lymphocytes increased 14.84 10.41 8 52369 272 29899829
Anticoagulation drug level above therapeutic 14.83 10.41 17 52360 1782 29898319
Osteonecrosis of jaw 14.80 10.41 7 52370 18611 29881490
Blood pressure increased 14.79 10.41 70 52307 71858 29828243
Granuloma skin 14.79 10.41 8 52369 274 29899827
Rhinalgia 14.71 10.41 9 52368 390 29899711
Gait disturbance 14.66 10.41 74 52303 74703 29825398
Bronchopleural fistula 14.61 10.41 9 52368 395 29899706
Seborrhoea 14.56 10.41 7 52370 186 29899915
Dyspnoea 14.55 10.41 717 51660 332578 29567523
Pain in extremity 14.54 10.41 123 52254 110098 29790003
Haemorrhoids thrombosed 14.49 10.41 7 52370 188 29899913
Contraindicated product administered 14.45 10.41 6 52371 17225 29882876
Anosmia 14.29 10.41 18 52359 2082 29898019
Lung opacity 14.27 10.41 12 52365 861 29899240
Cerebral toxoplasmosis 14.01 10.41 15 52362 1457 29898644
Viral rash 13.96 10.41 5 52372 61 29900040
Brain abscess 13.70 10.41 20 52357 2661 29897440
Tongue discolouration 13.62 10.41 13 52364 1102 29898999
Viral pharyngitis 13.61 10.41 6 52371 130 29899971
Tuberculosis gastrointestinal 13.57 10.41 7 52370 217 29899884
Hypogammaglobulinaemia 13.53 10.41 29 52348 5223 29894878
Rotavirus infection 13.52 10.41 8 52369 326 29899775
Disease progression 13.51 10.41 83 52294 79791 29820310
Eosinophilic pleural effusion 13.46 10.41 7 52370 221 29899880
Lip oedema 13.39 10.41 18 52359 2219 29897882
Blood pressure fluctuation 13.29 10.41 7 52370 17496 29882605
Asthenia 13.12 10.41 291 52086 220999 29679102
Cardiac failure congestive 13.11 10.41 90 52287 84317 29815784
Atypical mycobacterial infection 13.11 10.41 11 52366 787 29899314
Wrong dose 13.09 10.41 8 52369 346 29899755
Haemorrhagic cholecystitis 13.01 10.41 4 52373 29 29900072
Prothrombin level decreased 12.97 10.41 13 52364 1169 29898932
Plasma cell myeloma 12.85 10.41 49 52328 53413 29846688
Rheumatic fever 12.78 10.41 4 52373 31 29900070
Cutaneous extramedullary haemopoiesis 12.77 10.41 3 52374 6 29900095
Achromotrichia congenital 12.77 10.41 3 52374 6 29900095
Atrial conduction time prolongation 12.77 10.41 3 52374 6 29900095
Hepatotoxicity 12.64 10.41 64 52313 18081 29882020
Urinary retention 12.58 10.41 24 52353 32893 29867208
Rubber sensitivity 12.50 10.41 5 52372 84 29900017
Respiration abnormal 12.49 10.41 19 52358 2623 29897478
Toxic optic neuropathy 12.46 10.41 10 52367 672 29899429
Cystic fibrosis lung 12.40 10.41 5 52372 86 29900015
Sensation of foreign body 12.39 10.41 14 52363 1445 29898656
Hyponatraemia 12.34 10.41 68 52309 67134 29832967
Hypoxia 12.33 10.41 133 52244 47721 29852380
Pneumonia staphylococcal 12.26 10.41 20 52357 2931 29897170
Cognitive disorder 12.25 10.41 14 52363 23676 29876425
Therapeutic product effect decreased 12.19 10.41 20 52357 29056 29871045
Mycobacterial infection 12.11 10.41 15 52362 1706 29898395
Hypertension 12.03 10.41 145 52232 121209 29778892
Hyperkalaemia 12.01 10.41 67 52310 65943 29834158
Product dose omission issue 12.00 10.41 226 52151 91405 29808696
Diaphragmatic hernia 12.00 10.41 7 52370 278 29899823
Dysarthria 11.85 10.41 22 52355 30468 29869633
Interstitial granulomatous dermatitis 11.82 10.41 6 52371 180 29899921
Hypotension 11.81 10.41 264 52113 200301 29699800
Cheilitis 11.78 10.41 17 52360 2239 29897862
Hypocoagulable state 11.75 10.41 11 52366 910 29899191
Incorrect product administration duration 11.69 10.41 23 52354 3899 29896202
Cryptococcosis 11.56 10.41 15 52362 1787 29898314
Interstitial lung disease 11.56 10.41 60 52317 60137 29839964
Periorbital swelling 11.52 10.41 6 52371 190 29899911
Cardiac failure 11.49 10.41 92 52285 83326 29816775
Hyperacusis 11.31 10.41 9 52368 597 29899504
Bronchopulmonary aspergillosis 11.29 10.41 47 52330 12237 29887864
Mucormycosis 11.25 10.41 27 52350 5241 29894860
Pulmonary alveolar haemorrhage 11.23 10.41 31 52346 6550 29893551
Palmar-plantar erythrodysaesthesia syndrome 11.21 10.41 6 52371 14864 29885237
Stenotrophomonas infection 11.18 10.41 14 52363 1610 29898491
Lip ulceration 11.14 10.41 10 52367 783 29899318
Rash pustular 11.14 10.41 26 52351 4957 29895144
Pneumonia pneumococcal 11.14 10.41 15 52362 1852 29898249
Haemoglobin decreased 11.05 10.41 137 52240 113961 29786140
Acute sinusitis 11.04 10.41 13 52364 1403 29898698
Multiple allergies 10.97 10.41 16 52361 2127 29897974
Rhabdomyolysis 10.96 10.41 164 52213 63416 29836685
Contusion 10.94 10.41 24 52353 31256 29868845
Therapeutic response decreased 10.93 10.41 16 52361 24333 29875768
Urethral discharge 10.87 10.41 3 52374 14 29900087
Infective exacerbation of bronchiectasis 10.86 10.41 8 52369 473 29899628
Distributive shock 10.81 10.41 9 52368 637 29899464
Kaposi's sarcoma 10.72 10.41 11 52366 1017 29899084
Purpura senile 10.70 10.41 3 52374 15 29900086
Treatment failure 10.68 10.41 100 52277 34579 29865522
Q fever 10.65 10.41 5 52372 126 29899975
Product contamination microbial 10.62 10.41 9 52368 653 29899448
Nasopharyngitis 10.61 10.41 153 52224 58696 29841405
Interleukin-2 receptor increased 10.61 10.41 5 52372 127 29899974
Depressed level of consciousness 10.56 10.41 33 52344 38189 29861912
Forced expiratory volume increased 10.54 10.41 3 52374 16 29900085
Sputum retention 10.54 10.41 8 52369 495 29899606
Haematoma 10.50 10.41 16 52361 23937 29876164
Rash morbilliform 10.45 10.41 17 52360 2485 29897616
Tachyarrhythmia 10.42 10.41 19 52358 3042 29897059

Pharmacologic Action:

SourceCodeDescription
ATC J01FA10 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
Macrolides
ATC J01RA07 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
COMBINATIONS OF ANTIBACTERIALS
Combinations of antibacterials
ATC S01AA26 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFECTIVES
Antibiotics
FDA CS M0028311 Macrolides
FDA Chemical/Ingredient N0000007529 Macrolides
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
FDA EPC N0000175935 Macrolide Antimicrobial

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Acute gonococcal cervicitis indication 20943002 DOID:10615
Acute gonococcal urethritis indication 29864006
Streptococcal tonsillitis indication 41582007
Pneumonia due to Mycoplasma pneumoniae indication 46970008
Bacterial pneumonia indication 53084003 DOID:874
Haemophilus influenzae pneumonia indication 70036007
Acute bacterial sinusitis indication 75498004
Bacterial conjunctivitis indication 128350005 DOID:9700
Urethritis due to Chlamydia trachomatis indication 179101003
Pulmonary Mycobacterium avium complex infection indication 186342000
Chlamydial pelvic inflammatory disease indication 188463006
Acute bacterial bronchitis indication 233598009
Pneumococcal pneumonia indication 233607000
Chlamydial pneumonia indication 233609002
Chancroid indication 266143009 DOID:13778
Pelvic inflammatory disease due to Mycoplasma hominis indication 270550006
Streptococcus pyogenes infection indication 302809008
Infective otitis media indication 312218008
Infection due to Staphylococcus aureus indication 406602003
Acute exacerbation of chronic bronchitis indication 425748003
Pneumonia due to Staphylococcus aureus indication 441658007
Moraxella Catarrhalis Acute Otitis Media indication
Skin and Skin Structure Streptococcus Agalactiae Infection indication
Chlamydia Cervicitis indication
Legionella Pneumophila Pneumonia indication
Pelvic Inflammatory Disease with Neisseria Gonorrhea indication
Pneumococcal Acute Otitis Media indication
Haemophilus Influenzae Acute Otitis Media indication
Moraxella Catarrhalis Pneumonia indication
Pyrexia of unknown origin off-label use 7520000
Traveler's diarrhea off-label use 11840006
Enteric campylobacteriosis off-label use 18081009
Pertussis off-label use 27836007
Gonorrhea of rectum off-label use 42746002
Gonorrhea of pharynx off-label use 74372003
Coronavirus infection off-label use 186747009
Boutonneuse fever off-label use 186774005 DOID:14095
Toxoplasmosis associated with acquired immunodeficiency syndrome off-label use 421666009
Prevention of Bacterial Endocarditis off-label use
Inflammatory Disease of Female Pelvic Organs off-label use
Sexual Transmitted Disease Exposure from Sexual Assault off-label use
Jaundice contraindication 18165001
Torsades de pointes contraindication 31722008
Chronic heart failure contraindication 48447003
Myasthenia gravis contraindication 91637004 DOID:437
Prolonged QT interval contraindication 111975006
Hearing disorder contraindication 128540005
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Pseudomembranous enterocolitis contraindication 397683000
Congenital long QT syndrome contraindication 442917000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.45 acidic
pKa2 8.87 Basic
pKa3 8.24 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Canalicular multispecific organic anion transporter 1 Transporter IC50 4.16 WOMBAT-PK
Multidrug resistance protein 1 Transporter IC50 3.70 WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 3.39 WOMBAT-PK
Motilin receptor GPCR AGONIST EC50 5.50 IUPHAR
SARS-CoV-2 Virus INHIBITOR EC50 5.67 SCIENTIFIC LITERATURE

External reference:

IDSource
J2KLZ20U1M UNII
4020019 VUID
N0000148074 NUI
D02134 KEGG_DRUG
117772-70-0 SECONDARY_CAS_RN
4020019 VANDF
4020964 VANDF
C0052796 UMLSCUI
ZIT PDB_CHEM_ID
CHEMBL529 ChEMBL_ID
CHEMBL1200502 ChEMBL_ID
DB00207 DRUGBANK_ID
D017963 MESH_DESCRIPTOR_UI
447043 PUBCHEM_CID
6197 INN_ID
6510 IUPHAR_LIGAND_ID
1298839 RXNORM
4238 MMSL
72442 MMSL
d00091 MMSL
003635 NDDF
387531004 SNOMEDCT_US
391805000 SNOMEDCT_US
734459003 SNOMEDCT_US
785687007 SNOMEDCT_US
96034006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Zithromax HUMAN PRESCRIPTION DRUG LABEL 1 0069-0400 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS NDA 28 sections
ZITHROMAX HUMAN PRESCRIPTION DRUG LABEL 1 0069-3051 POWDER, FOR SUSPENSION 1 g ORAL NDA 30 sections
Zithromax HUMAN PRESCRIPTION DRUG LABEL 1 0069-3060 TABLET, FILM COATED 250 mg ORAL NDA 29 sections
Zithromax HUMAN PRESCRIPTION DRUG LABEL 1 0069-3070 TABLET, FILM COATED 500 mg ORAL NDA 29 sections
ZITHROMAX HUMAN PRESCRIPTION DRUG LABEL 1 0069-3080 TABLET, FILM COATED 600 mg ORAL NDA 30 sections
Zithromax HUMAN PRESCRIPTION DRUG LABEL 1 0069-3110 POWDER, FOR SUSPENSION 100 mg ORAL NDA 29 sections
Zithromax HUMAN PRESCRIPTION DRUG LABEL 1 0069-3120 POWDER, FOR SUSPENSION 200 mg ORAL NDA 29 sections
Zithromax HUMAN PRESCRIPTION DRUG LABEL 1 0069-3130 POWDER, FOR SUSPENSION 200 mg ORAL NDA 29 sections
Zithromax HUMAN PRESCRIPTION DRUG LABEL 1 0069-3140 POWDER, FOR SUSPENSION 200 mg ORAL NDA 29 sections
Zithromax HUMAN PRESCRIPTION DRUG LABEL 1 0069-3150 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS NDA 28 sections
Zithromax HUMAN PRESCRIPTION DRUG LABEL 1 0069-4061 TABLET, FILM COATED 250 mg ORAL NDA 29 sections
Zithromax HUMAN PRESCRIPTION DRUG LABEL 1 0069-9500 TABLET, FILM COATED 250 mg ORAL UNULLPPROVED DRUG FOR USE IN DRUG SHORTAGE 32 sections
Azithromycin HUMAN PRESCRIPTION DRUG LABEL 1 0093-2026 POWDER, FOR SUSPENSION 200 mg ORAL ANDA 27 sections
Azithromycin HUMAN PRESCRIPTION DRUG LABEL 1 0093-2027 POWDER, FOR SUSPENSION 100 mg ORAL ANDA 27 sections
Azithromycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-0144 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 26 sections
Azithromycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-0144 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 26 sections
azithromycin HUMAN PRESCRIPTION DRUG LABEL 1 0527-2370 TABLET, FILM COATED 250 mg ORAL ANDA 28 sections
azithromycin HUMAN PRESCRIPTION DRUG LABEL 1 0527-2381 TABLET, FILM COATED 600 mg ORAL ANDA 30 sections
azithromycin HUMAN PRESCRIPTION DRUG LABEL 1 0527-2395 TABLET, FILM COATED 500 mg ORAL ANDA 28 sections
Azithromycin Dihydrate HUMAN PRESCRIPTION DRUG LABEL 1 0527-2750 TABLET, COATED 500 mg ORAL Unapproved drug for use in drug shortage 2 sections
Azithromycin HUMAN PRESCRIPTION DRUG LABEL 1 0781-5776 TABLET, FILM COATED 250 mg ORAL ANDA 27 sections
Azithromycin HUMAN PRESCRIPTION DRUG LABEL 1 0781-5789 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections
Azithromycin HUMAN PRESCRIPTION DRUG LABEL 1 0781-5793 TABLET, FILM COATED 600 mg ORAL ANDA 26 sections
Azithromycin HUMAN PRESCRIPTION DRUG LABEL 1 0781-8089 TABLET, FILM COATED 250 mg ORAL ANDA 27 sections
Azithromycin HUMAN PRESCRIPTION DRUG LABEL 1 0781-8090 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections
Azithromycin HUMAN PRESCRIPTION DRUG LABEL 1 0781-8091 TABLET, FILM COATED 600 mg ORAL ANDA 26 sections
azithromycin monohydrate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6708 TABLET 250 mg ORAL ANDA 26 sections
azithromycin monohydrate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6909 TABLET 500 mg ORAL ANDA 26 sections
azithromycin HUMAN PRESCRIPTION DRUG LABEL 1 10019-648 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS NDA AUTHORIZED GENERIC 30 sections
Azithromycin Human Prescription Drug Label 1 16571-695 TABLET, FILM COATED 250 mg ORAL ANDA 27 sections